US2019249097(SHELL OIL CO [US])
[0017] It is preferred to avoid inclusion of tert.butanol or MTBE.
【００１８】
ｔｅｒｔ－ブタノールまたはＭＴＢＥの包含を避けることが好ましい。
Accordingly, preferred gasoline compositions of the present invention contain 0 to 10% by volume of at least one oxygenate selected from methanol, ethanol, isopropanol and isobutanol.
したがって、本発明の好ましいガソリン組成物は、メタノール、エタノール、イソプロパノール、およびイソブタノールから選択される少なくとも１つの含酸素添加剤を０～１０体積％含有する。
US9981848(SAUDI ARABIAN OIL CO [SA])
In at least one embodiment of the present invention, acid gas stream 10 contains less than about 55% by volume H2 S.
本発明の少なくとも１つの実施形態では、酸性ガス流体１０は、Ｈ２Ｓを約５５体積％未満含有する。
In some embodiments of the present invention, acid gas stream 10 contains between about 15% and about 55% by volume H2 S, alternately between about 15% and about 40% by volume H2 S,
本発明の幾つかの実施形態では、酸性ガス流体１０はＨ２Ｓを、約１５体積％～約５５体積％、約１５体積％～約４０体積％、
alternately between about 15% and about 30% by volume H2 S, alternately between about 15% and about 25% by volume H2 S,
約１５体積％～約３０体積％、約１５体積％～約２５体積％、
alternately between about 15% and about 20% by volume H2 S, and alternately between about 25% and about 40% by volume H2 S.
１５体積％～約２０体積％、約２５体積％～約４０体積％含有する。
US11938135(UNIV JOHNS HOPKINS [US])
The compositions of the invention could also be formulated as nanoparticle formulations.
【０２０５】
本発明の組成物はナノ粒子製剤として製剤化することもできる。
The compounds of the invention can be administered for immediate-release, delayed-release, modified-release, sustained-release, pulsed-release and/or controlled-release applications.
本発明の化合物は、即時放出、遅延放出、調節放出、持続放出、パルス放出および／または制御放出適用のために投与することができる。
The pharmaceutical compositions of the invention may contain from 0.01 to 99% weight-per volume of the active material.
本発明の薬学的組成物は、活性材料を0.01～99重量体積%含有し得る。
US11384266(3M INNOVATIVE PROPERTIES CO [US])
Generally, the compositions can contain, for example, from about 30 to about 80 (preferably, from about 45 to about 70) volume percent fibers, depending upon structural application requirements.
一般に、組成物は、構造的用途の要求に応じて、例えば、繊維を約３０～約８０（好ましくは、約４５～約７０）体積％含有し得る。
